Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

被引:135
作者
Dahut, WL
Lakhani, NJ
Gulley, JL
Arlen, PM
Kohn, EC
Kotz, H
McNally, D
Parr, A
Nguyen, D
Yang, SX
Steinberg, SM
Venitz, J
Sparreboom, A
Figg, WD
机构
[1] NCI, Med Oncol Clin Res Unit, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Biostat & Data Management Sect, Ctr Canc Res, Bethesda, MD 20892 USA
[3] Virginia Commonwealth Univ, Dept Pharmaceut, Richmond, VA USA
关键词
2-methoxyestradiol (2ME2); phase I; clinical trial; angiogenesis; solid tumor; apoptosis;
D O I
10.4161/cbt.5.1.2349
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the maximum-tolerated dose (MTD) and toxicity profile of the novel anticancer agent, 2-methoxyestradiol (2ME2) administered orally, in patients with solid tumors. Materials and methods: Twenty patients with refractory solid tumors were enrolled. 2ME2 was given orally starting at 400 mg bid with dose escalation until 3000 mg bid. Tumor biopsies were taken before and after starting the drug to assess for microvessel density by CD 31 and cell proliferation by Ki67 immunohistochemistry. Serial plasma samples collected up to 50 hours after first single oral dose for characterization of pharmacokinetics, were analyzed using liquid chromatography tandem mass-spectrometry. Results: Eleven men and nine women received 2ME2 at dose levels of 400 mg bid (n=3), 800 mg bid (n=3), 1600 mg bid (n=6), 2200 mg bid (n=5) and 3000 mg bid (n=3). There were no dose limiting toxicities, therefore the MTD was not defined. There was one episode of grade 4 angioedema in the 1600 mg bid dose level 38 days into 2ME2 treatment. Other toxicities were mild to moderate. A patient with clear cell carcinoma of the ovary had a partial response at 1600 mg bid dose level lasting over three years. Conclusion: MTD for 2ME2 was not reached at dose of 3000 mg bid. The trial was closed due to extremely low plasma concentrations of 2ME2 relative to the doses administered. 2ME2 treatment had no effect on microvessel density (CD31 immunostaining) and cell proliferation (Ki-67 immunostaining). A new formulation of 2ME2 with improved bioavailability is currently being developed.
引用
收藏
页码:22 / 27
页数:6
相关论文
共 32 条
[1]  
[Anonymous], NONPARAMETRIC STAT M
[2]   Clinical characteristics of clear cell carcinoma of the ovary [J].
Behbakht, K ;
Randall, TC ;
Benjamin, I ;
Morgan, MA ;
King, S ;
Rubin, SC .
GYNECOLOGIC ONCOLOGY, 1998, 70 (02) :255-258
[3]   SERUM CONCENTRATION AND URINARY-EXCRETION OF CLASSICAL ESTROGENS, CATECHOLESTROGENS AND 2-METHOXYESTROGENS IN NORMAL HUMAN-PREGNANCY [J].
BERG, FD ;
KUSS, E .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1992, 251 (01) :17-27
[4]  
Biing Jiunn-Tang, 1994, Proceedings of the National Science Council Republic of China Part B Life Sciences, V18, P64
[5]   2-METHOXYESTRADIOL, AN ENDOGENOUS MAMMALIAN METABOLITE, INHIBITS TUBULIN POLYMERIZATION BY INTERACTING AT THE COLCHICINE SITE [J].
DAMATO, RJ ;
LIN, CM ;
FLYNN, E ;
FOLKMAN, J ;
HAMEL, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3964-3968
[6]   Oral chemotherapy: Rationale and future directions [J].
DeMario, MD ;
Ratain, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2557-2567
[7]  
Ee Rachel P. L., 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P113
[8]  
FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
[9]   Transepithelial transport and cellular accumulation of steroid hormones and polychlorobiphenyl in porcine kidney cells expressed with human P-glycoprotein [J].
Fujise, H ;
Annoura, T ;
Sasawatari, S ;
Ikeda, T ;
Ueda, K .
CHEMOSPHERE, 2002, 46 (9-10) :1505-1511
[10]   Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease [J].
Goff, BA ;
delaCuesta, RS ;
Muntz, HG ;
Fleischhacker, D ;
Ek, M ;
Rice, LW ;
Nikrui, N ;
Tamimi, HK ;
Cain, JM ;
Greer, BE ;
Fuller, AF .
GYNECOLOGIC ONCOLOGY, 1996, 60 (03) :412-417